Revance Therapeutics, Inc.
| Public | |
| Traded as | NASDAQ: RVNC |
| ISIN | 🆔 |
| Industry | Biotechnology |
| Founded 📆 | August 10, 1999 in Nashville, TN |
| Founders 👔 | Jacob M. Waugh L. Daniel Browne |
| Headquarters 🏙️ | , 1222 Demonbreun St. Nashville, TN 37203 |
Area served 🗺️ | |
Key people | Mark Foley, CEO |
| Members | |
Number of employees | |
| 🌐 Website | www |
| 📇 Address | |
| 📞 telephone | |
Revance Therapeutics, Inc. is an American pharmaceutical company. Revance is headquartered in Nashville, Tennessee. The company was founded on August 10, 1999, and is listed on the Nasdaq stock exchange.
Company overview
Revance is one of a handful of companies in the global facial injectables market, which is projected to reach $9.07 billion by 2028.[1][2][3][4]
Products and services
Revance has two business units: aesthetics and therapeutics. The primary product for both units is DaxibotulinumtoxinA, or DAXI for short. DAXI is a botulinum toxin designed to block nerve signals leading to muscles. Typically, botulinum toxins are delivered via injection and are used for treating muscle spasms and for cosmetic treatment of wrinkles.[5] According to company officials, Revance's DAXI product could be applied through a topical gel.[6]
Revance's aesthetics unit is using DAXI as a facial treatment for wrinkles. Revance's therapeutics unit is examining DAXI for use in several other areas, including treatment of cervical dystonia; adult upper limb spasticity, a neurologic condition that affects movement in the arms or hands and occurs most commonly after a stroke or brain injury; plantar fasciitis; and migraine headaches.[7]
Partnerships
Revance has created several partnerships, including a distribution agreement to market dermal fillers made by Teoxane Laboratories, a Swiss company, in the United States. Revance is also partnering with Viatris, Inc., allowing Revance to compete in the short-acting neuromodulator market. Finally, Revance has contracted with Fosun Pharma to market Revance offerings in China.[8]
U.S. offices
Revance is headquartered in Nashville, Tennessee, and has three corporate offices in California, including in Irvine, where the company performs its commercialization; Pleasanton, where it works on technology; and Newark, where it conducts manufacturing and research and development.[9]
Stock market
Revance is traded on the Nasdaq exchange under the symbol RVNC. Its stock price has fluctuated as it awaits approval by the U.S. Food and Drug Administration.[10][11] In October 2021, the FDA denied Revance's application due to manufacturing issues, and Revance has renewed its talks with the regulator to seek approval for treatment of frown lines.[12]
See also
- Injectable filler
References
- ↑ "Facial Injectables Market to Reach USD 9.07 Billion by 2028". Yahoo!Finance. January 31, 2022. Retrieved February 22, 2022.
- ↑ Erman, Michael (September 14, 2018). "Allergan says revenue from aesthetics unit may double by 2025". Reuters. Retrieved February 22, 2022.
- ↑ Hopkins, Jared (April 8, 2019). "Botox Rivals Create New Wrinkles for Allergan". Wall Street Journal. Retrieved February 22, 2022.
- ↑ "Deion Sanders Loves BOTOX And Is Getting His Message Out To Men". Forbes. January 15, 2018. Retrieved February 22, 2022.
- ↑ "Overview of DaxibotulinumtoxinA for Injection: A Novel Formulation of Botulinum Toxin Type A". National Institutes of Health National Library of Medicine. November 17, 2012. Retrieved February 22, 2022.
- ↑ Dador, Denise (February 23, 2016). "Gel could offer Botox benefit without needles". KABC-TV< Los Angeles. Retrieved February 22, 2022.
- ↑ "Revance Therapeutics". Revance website. Retrieved February 23, 2022.
- ↑ "Partnerships". Revance Therapeutics website. Retrieved February 22, 2022.
- ↑ "About Revance". Revance Therapeutics website. Retrieved February 22, 2022.
- ↑ Miao, Hannah (October 18, 2021). "Stocks making the biggest moves midday". CNBC. Retrieved February 22, 2022.
- ↑ Grover, Divya (December 13, 2017). "Revance will wait to seek backing for Botox-rival". Reuters. Retrieved February 22, 2022.
- ↑ Kellaher, Colin (January 7, 2022). "Revance Therapeutics Rises After FDA Meeting on DAXI". Retrieved February 22, 2022.
External links
This article "Revance" is from Wikipedia. The list of its authors can be seen in its historical and/or the page Edithistory:Revance. Articles copied from Draft Namespace on Wikipedia could be seen on the Draft Namespace of Wikipedia and not main one.
